Skip to content
  • Sunday, 26 July 2026
  • 1:45 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Laboratory Automation & Robotics

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s

Lana Keisha Jul 25, 2026 0

A new paradigm in therapeutic development is emerging as Remepy, a pioneering startup, successfully completed a Phase IIa clinical trial…

Read More
Laboratory Automation & Robotics

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s

Lana Keisha Jul 10, 2026 0

A new era in therapeutic innovation is dawning, marked by the successful Phase IIa clinical trial results for Hybridopa, an…

Read More
Laboratory Automation & Robotics

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s

Lana Keisha Jun 29, 2026 0

In a significant advancement for integrated medicine, Remepy, a pioneering startup, has announced successful Phase IIa clinical trial results for…

Read More
Laboratory Automation & Robotics

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s.

Lana Keisha Jun 22, 2026 0

A significant stride in the realm of integrated medicine has been reported by Remepy, a pioneering startup, as its innovative…

Read More
Neuroscience & Brain Research

Copper drug clears toxic Alzheimer’s proteins and restores memory

Rifan Muazin Jun 16, 2026 0

In a significant advancement for neuropharmacology, researchers at Monash University have identified a copper-based drug candidate that demonstrates a dual-action…

Read More
Laboratory Automation & Robotics

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s

Lana Keisha Jun 15, 2026 0

In a significant advancement for integrated medicine, Remepy, a pioneering startup, has announced successful Phase IIa clinical trial results for…

Read More
Laboratory Automation & Robotics

First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?

Lana Keisha Apr 4, 2026 0

For decades, successive waves of antidepressants have promised relief to millions suffering from mood disorders, yet the landscape for those…

Read More
Laboratory Automation & Robotics

First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?

Lana Keisha Mar 27, 2026 0

For decades, the medical community has grappled with the persistent challenge of mood disorders, offering successive waves of antidepressants that,…

Read More
Laboratory Automation & Robotics

First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?

Lana Keisha Mar 20, 2026 0

The landscape of mental health treatment witnessed a significant development on February 17, 2026, as Compass Pathways, a leading mental…

Read More
Opdivo Secures Landmark US and EU Approvals for Classical Hodgkin Lymphoma Across Pediatric and Adult PopulationsFirst-of-its-Kind Implant Promises Dramatic Improvement for Severe Tissue Loss TreatmentDeloitte report showed pharma returns rising to 7%. GLP-1s did most of the work.University of Arizona Study Reveals Human Heart Muscle Regeneration in Patients with Artificial Pumps Opening Potential Paths to Curing Heart Failure
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ